Atlas Trials

A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy

Clinical trial NCT03167203 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT03167203
Sponsor
Astellas Institute for Regenerative Medicine
Status
ENROLLING_BY_INVITATION
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Macular Degenerative Disease
Start date
2018-01-08
Primary completion
2029-03-31
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.